We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.42%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$137M
AUM Growth
-$1.43M
(-1%)
Cap. Flow
+$3.85M
Cap. Flow
% of AUM
2.8%
Top 10 Holdings %
Top 10 Hldgs %
73.24%
Holding
64
New
1
Increased
15
Reduced
6
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ovintiv
OVV
|
+$2.58M |
| 2 |
Prothena Corp
PRTA
|
+$1.77M |
| 3 |
Phreesia
PHR
|
+$1.6M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$933K |
| 5 |
Biodesix
BDSX
|
+$908K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$2.06M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$647K |
| 4 |
United Therapeutics
UTHR
|
+$610K |
| 5 |
Vanda Pharmaceuticals
VNDA
|
+$518K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.73% |
| 2 | Energy | 3.94% |
| 3 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Stoke Therapeutics
STOK
$1.74B
| $198K | 0.14% |
15,000
| – | – |
|
|
GTHX
52
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $198K | 0.14% |
40,000
| – | – |
|
|
ISEE
53
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $144K | 0.1% |
15,000
| – | – |
|
54
InflaRx
IFRX
$271M
| $102K | 0.07% |
70,000
| – | – |
|
|
CNCE
55
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $84K | 0.06% |
20,000
| – | – |
|
56
Elicio Therapeutics
ELTX
$79.8M
| $62K | 0.05% |
5,439
| – | – |
|
57
Laird Superfood
LSF
$47.9M
| $53K | 0.04% |
28,000
| – | – |
|
|
AWH
58
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $49K | 0.04% |
5,540
-1,334
| -19% | -$13.5K |
|
|
YTEN
59
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| $42K | 0.03% |
781
| – | – |
|
|
SIEN
60
DELISTED
Sientra, Inc.
SIEN
| $34K | 0.02% |
4,000
| – | – |
|
61
Akebia Therapeutics
AKBA
$341M
| – | – |
-20,000
| Closed | -$8.39K |
|
|
AMRN
62
Amarin Corp
AMRN
$286M
| – | – |
-15,000
| Closed | -$647K |
|
|
63
Biogen
BIIB
$30B
| – | – |
-10,100
| Closed | -$2.06M |
|
|
64
Vanda Pharmaceuticals
VNDA
$323M
| – | – |
-50,000
| Closed | -$518K |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Birchview Capital held 64 positions worth $137M, down 1% from $139M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Birchview Capital's Q2 2022 filing shows 1 new, 15 increased, 6 reduced and 4 closed positions. Its largest new stake was Xenon Pharmaceuticals: 10,000 shares worth $304K. The largest sale was Biogen, an estimated $2.06M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy and Consumer Staples.
- Birchview Capital's largest Q2 2022 buy was Xenon Pharmaceuticals: 10,000 shares worth $304K.
- Birchview Capital added most to Ovintiv in Q2 2022, an estimated $2.58M increase.
- Birchview Capital's biggest Q2 2022 reduction was Bristol-Myers Squibb, cutting an estimated $2M.
- Birchview Capital fully exited Biogen in Q2 2022, selling an estimated $2.06M.
- Birchview Capital's ten largest holdings make up 73% of its $137M portfolio in Q2 2022.
- Birchview Capital opened 1 new position and closed 4 in Q2 2022.
- Birchview Capital's portfolio value fell 1% quarter-over-quarter to $137M.
Based on Birchview Capital's 13F filing for Q2 2022, filed 12 Aug 2022.